References
- Nederlandse Vereniging voor Neurologie. Richtlijn Multiple Sclerose 2012, Nederlandse Vereniging voor Neurologie, Utrecht, The Netherlands. Editor: Bohn Stafleu van Loghum, Houten, The Netherlands.
- Zorginstituut Nederland. Middelen bij multipele sclerose. Farmacotherapeutisch kompas. Available from: https://www.farmacotherapeutischkompas.nl/inleidendeteksten/i/inlmiddelenbijmultipelesclerose.asp Zorginstituut Nederlands, Diemen, The Netherlands. [Last accessed 25 November 2015]
- Karampampa K, Gustavsson A, van Munster ETL, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ 2013;16:939-50
- Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7(Suppl 2):S55-S64
- Zorginstituut Nederland. Alemtuzumab (Lemtrada) bij actieve relapsing remitting multiple sclerose (RRMS). Zorginstituut Nederland, Diemen, The Netherlands; 2016. Accessible through: https://www.zorginstituutnederland.nl/publicaties/rapport/2016/03/24/alemtuzumab-lemtrada-bij-actieve-relapsing-remitting-multiple-sclerose-rrms
- Kappos L, Radue E, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
- Polman C, O’Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
- Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
- Cohen J, Coles A, Arnold D, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
- Institute for Clinical and Economic Review (ICER). Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value. ICER, Boston, Massachusetts, United States. Available through: https://icer-review.org/wp-content/uploads/2016/08/CTAF_MS_Final_Report_030617.pdf [Last accessed March 28, 2018]
- Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2015; Issue 9
- GRADE Working Group. Grading of recommendations assessment, development and evaluation. Available from: http://www.gradeworkinggroup.org/ [Accessed: 28 March 2018]
- Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of health care programmes. 3rd edn. New York: Oxford University Press; 2005
- Fox EJ, Arnold DL, Cohen JA, et al. Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 4 years. Eur Congr Treat Res Mult Scler 2015:P1102
- Havrdova E, Arnold D, Cohen J, et al. Durable efficacy of alemtuzumab on clinical outcomes over 5 years in treatment-naive patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 year: CARE-MS I extension study. Abstract published in: Multiple Sclerosis Journal, Volume 21 Issue 11 Supplement, September 2015.
- Organisation for Economic Co-operation and Development (OECD). Harmonized consumer price index. Available from: http://stats.oecd.org/. OACD, Paris, France. [Last accessed 29 September 2015]
- Zorginstituut Nederland. Richtlijn Voor Het Uitvoeren van Economische Evaluaties in de Gezondheidszorg. Zorginstituut Nederland, Diemen, The Netherlands; 2015
- Novartis Europharm Limited. Summary of product characteristics Gilenya. Novartis, Horsham, UK; 2011
- Elan Pharma International Ltd. Summary of product characteristics Tysabri. Elan Pharma International Ltd, Athlone, Ireland; 2006.
- Genzyme Therapeutics Ltd. Summary of product characteristics Lemtrada. Genzyme Therapeutics Ltd, Oxford. UK; 2014
- Hospital protocol 1. Hospital Protocol: Natalizumab (Tysabri); 2015
- Hospital protocol 2. Hospital Protocol: Fingolimod (Gilenya); 2015
- Hospital protocol 3. Hospital Protocol: Alemtuzumab (Lemtrada); 2015
- Zorginstituut Nederland. Medicijnkosten. Available from: https://www.medicijnkosten.nl/ Zorginstituut Nederland, Diemen, The Netherlands. [Last accessed 13 October 2015]
- Nederlandse Zorgautoriteit (NZa). DBC zorgproducten tariefapplicatie. Available from: http://dbc-zorgproducten-tarieven.nza.nl/nzaZpTarief/ZoekfunctieDot.aspx NZa, Utrecht, The Netherlands. [Last accessed 13 October 2015]
- Nederlandse Zorgautoriteit (NZa). Open DIS Data. Available from: http://www.opendisdata.nl/zorgproduct/ NZa, Utrecht, The Netherlands. [Last accessed 15 March 2016]
- Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, et al. Kostenhandleiding: Methodologie van Kostenonderzoek En Referentieprijzen Voor Economische Evaluaties in de Gezondheidszorg. Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; 2015
- Nationaal Kompas Volksgezondheid RIVM. Cijfers multiple sclerose 2007 (prevalentie, incidentie en sterfte naar leeftijd en geslacht). RIVM, Bilthoven, The Netherlands, 2017. Available from: http://www.nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-aandoeningen/achtergrondcijfers-bij-rangordetabellen/ [Accessed 28 September 2015]
- Donker G, van der Haar E. Waterpokken: vaccinatie invoeren of niet? Huisarts Wet 2009;52:165
- European Medicines Agency (EMA)/Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report (EPAR)- Alemtuzumab. EMA/CHMP; London, UK; 2013
- De Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-70
- European Medicines Agency (EMA). New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya. EMA, London, UK; 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1 [Last accessed 14 November 2017]
- Borchardt J, Berger J. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler Relat Disord 2016;8:145-50
- VUmc MS Centrum Amsterdam. Natalizumab (Tysabri®). VUmc, Amsterdam, The Netherlands; 2015 Available from: https://www.vumc.nl/afdelingen/patientenfolders-brochures/zoeken-alfabet/T/tysabri_natalizumab.pdf [Last accessed 11 January 2018]
- Wattjes MP, Wijburg MT, Vennegoor A, et al. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry 2016;87:879-84
- Tandvårds- och läkemedelsförmånsverket. Lemtrada (Alemtuzumab): Hälsoekonomiskt Kunskapsunderlag. Tandvårds- och läkemedelsförmånsverket (TLV) , Stockholm, Sweden; 2014
- National Institute of Health and Care Excellence. TA312: Alemtuzumab for treating relapsing remitting multiple sclerosis. NICE, London, UK; 2014. Available from: https://www.nice.org.uk/guidance/ta312/history [Last accessed 23 November 2017].
- Canadian Agency for Drugs and Technologies in Health. CDEC final recommendation: Alemtuzumab. CADTH, Ottawa, Canada; 2015. Available from: https://www.cadth.ca/sites/default/files/cdr/complete/cdr-complete-SR0405-Lemtrada-June-22-2015.pdf [Last accessed 23 November 2017]
- Van Rossum J, Vennegoor A, Killestein J. The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients: a follow-up study. Mult Scler 2014;20:1668-9
- Alroughani R. High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings. Mult Scler 2014;20:1667-8
- Nederlandse Zorgautoriteit (NZa). Ziekenhuisopname met maximaal 5 verpleegdagen tijdens een eerste behandeltraject bij multipele sclerose in 2015. Zorgproduct 069599018. Open DIS Data. NZa; Utrecht, The Netherlands; 2016. Available from: www.opendisdata.nl [Last accessed 20 January 2016]
- Fortin J, Jacques F, Siktai Fokko V, et al. Switching from natalizumab to alemtuzumab in patients with RRMS: real-world experience. In: European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS Online Library. 14 September, 2016:EP1498
- LaGanke C, Adcock A. Clinical outcomes of 200 multiple sclerosis patients switching from natalizumab to alemtuzumab in a single United States MS center (P3.117). Neurology 2016;86(16 Suppl) http://n.neurology.org/content/86/16_Supplement/P3.117
- Ayrinac X. Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France. In: European Committee for Treatment and Research in Multiple Sclerosis; 2017:P1149. ECTRIMS Online Library. 27 October, 2017; 200804 (https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/200804/xavier.ayrignac.efficacy.and.safety.of.alemtuzumab.in.150.patients.with.active.html?f=media=1)
- Thomas K. Observational study to evaluate real-world effectiveness in multiple sclerosis patients treated with alemtuzumab in Germany: TREAT-MS study preliminary results. In: European Committee for Treatment and Research in Multiple Sclerosis 2. 2017;EP1680. ECTRIMS Online Library, 25 October, 2017; 199700 (http://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199700/katja.thomas.observational.study.to.evaluate.real-world.effectiveness.in.html)
- Willis M, Harding K, Pickersgill T, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Scler J 2016;22:1215-23
- Kalincik T, Brown JWL, Robertson N, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol 2017;16:271-81